Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis
Top Cited Papers
- 14 September 2008
- Vol. 113 (6) , 1446-1452
- https://doi.org/10.1002/cncr.23714
Abstract
BACKGROUND. Few studies have examined the costs of supportive care for radiochemotherapy‐induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications. METHODS. The authors identified a retrospective cohort of patients with HNC or nonsmall lung cancer (NSCLC) who had received radiochemotherapy at 1 of 3 Chicago hospitals (a Veterans Administration hospital, a county hospital, or a tertiary care hospital). Charts were reviewed for the presence/absence of severe mucositis/pharyngitis and the medical resources that were used. Resource estimates were converted into cost units obtained from standard sources (hospital bills, Medicare physician fee schedule, Red Book). Estimates of resources used and direct medical costs were compared for patients who did and patients who did not develop severe mucositis/pharyngitis. RESULTS. Severe mucositis/pharyngitis occurred in 70.1% of 99 patients with HNC and in 37.5% of 40 patients with NSCLC during radiochemotherapy. The total median medical costs per patient were $39,313 for patients with mucositis/pharyngitis and $20,798 for patients without mucositis/pharyngitis (P = .007). Extended inpatient hospitalization accounted for $12,600 of the increased medical costs (median 14 days [$19,600] with severe mucositis/pharyngitis vs 5 days [$7000] without; P = .017). For patients who had HNC with mucositis/pharyngitis, incremental inpatient hospitalization costs were $14,000, and total medical costs were $17,244. For patients who had NSCLC with mucositis/pharyngitis, these costs were $11,200 and $25,000, respectively. CONCLUSIONS. In the current study, the medical costs among the patients with HNC and NSCLC who received radiochemotherapy were greater for those who developed severe mucositis/pharyngitis than for those who did not. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 9 references indexed in Scilit:
- Chemoradiotherapy for Locally Advanced Head and Neck CancerJournal of Clinical Oncology, 2007
- Cancer-Associated Neutropenic Fever: Clinical Outcome and Economic Costs of Emergency Department CareThe Oncologist, 2007
- Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck MalignanciesInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal CancerNew England Journal of Medicine, 2003
- The burdens of cancer therapyCancer, 2003
- Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019Journal of Clinical Oncology, 2002
- Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer PatientsThe Oncologist, 2001
- Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical TrialCancer Investigation, 2001
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin DiseaseAnnals of Internal Medicine, 1992